FDC Ltd. Share Price

Overview

FDC Ltd. share price is currently ₹327.41, up by ₹9.69 (3.05%) from its previous closing price of ₹317.72. The share price has declined -4.97% over the past month and declined -27.94% over the past year. The stock's 52-week low and high are ₹308.53 and ₹470.34, respectively. FDC Ltd. has a market capitalisation of ₹ 5,470.00 Cr. The share price was last updated on 09 Oct 2026, 03:57 PM IST.

FDC Ltd.
FDC Ltd.
FDC
 ₹0.00
 ₹9.69
3.05%
Healthcare
 ₹0.00(%)1D

Updated: 09 Oct 2026, 03:57:37 pm IST

Market Data

Open Price

 ₹322.13

Prev. Close

 ₹317.72
 ₹318.51

Day Low

 ₹329.15

Day High

 ₹308.53

52 Week Low

 ₹470.34

52 Week High

HealthcarePharmaceuticals & Drugs
CategorySmall Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

18.22

Sector PE

43.59

PB Ratio

2.14

Sector PB

5.76

EPS

17.97

Dividend Yield

1.56

Today's Volume

76.315 K

5 Day Avg. Volume

95.366 K

PEG Ratio

3.32

Market Cap.

₹ 5,470.00 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

ActionsEx-DateRecord-Date
DividendsInterim Dividend of 500% at ₹5/Share
11-Feb-202611-Feb-2026
DividendsInterim Dividend of 500% at ₹5/Share
22-Nov-202422-Nov-2024

Mutual Fund Ownership

Mutual Fund Holder
Jul 26
Shares held
Aug 26
Shares held
Nippon India Small Cap Fund - Growth42.75 Lac
42.75 Lac
no change
ICICI Prudential Small Cap Fund - Growth16.88 Lac
16.63 Lac
(1.48%)
ICICI Prudential Healthcare Fund - Growth-
12.82 Lac
(100%)
Tata India Pharma & Healthcare Fund - Regular Plan - Growth8.99 Lac
9.76 Lac
(8.55%)
ICICI Prudential ESG Exclusionary Strategy Fund - Growth6.59 Lac
6.59 Lac
no change

About FDC Ltd. 👋

FDC Limited is an India-based company, which is principally engaged in the business of manufacturing and trading of pharmaceutical products. The Company is specialized in manufacturing Oral Rehydration Solutions (ORS), energy drinks, antibiotics and ophthalmic therapies. Its products include Albuterol Sulfate, Bromhexine Hydrochloride, Cinnarizine, Flunarizine Dihydrochloride, Flurbiprofen Sodium, Miconazole Nitrate, Timolol Maleate, Amoxycillin + Clavulanic Acid, Rupatadine Fumarate, Salbutamol Sulphate, Kaolin Light/ Pectin, among others. The Company's product offerings cover an extensive range of categories, including anti-infectives, gastrointestinal treatments, ophthalmic, vitamins, minerals, dietary supplements, cardiovascular solutions, anti-diabetics, respiratory care, gynecology, dermatology and analgesics. Its various brands include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl and Mycoderm.

Expert Opinions

Insights from SEBI-registered analysts · updated live

Explore all →
Naveen Kumar

Naveen Kumar

28 May • 5:27 AM · SEBI-Registered Analyst

FDC

FDC Limited is a Mumbai-based mid-size pharma company. You might know their brands — Electral (ORS sachets), Enerzal (energy drink), Zifi, Zocon : these are household names. They sell both in India and export internationally. Now the actual numbers (Consolidated, directly from the filing): Q4 FY26 Revenue: ₹584.8 Cr — up a solid 19% YoY from ₹491.9 Cr last Q4. Strong growth! Q4 FY26 PAT (Net Profit): ₹103.4 Cr — up a jaw-dropping 167% YoY from just ₹38.7 Cr in Q4 last year. That's nearly 3x profit in a single quarter! FY26 Full Year Revenue: ₹2,170 Cr — modest 3% growth over FY25's ₹2,108 Cr. FY26 Full Year PAT: ₹281 Cr — up ~5.5% from FY25's ₹267 Cr. Past Trend Check: Here's the real story : FY25 was actually a BAD year for FDC. Revenue grew 8.5% but PAT fell by 12.5% due to margin pressure. FY24 PAT was ₹305 Cr, FY25 dropped to ₹267 Cr. So FY26 PAT at ₹281 Cr is a recovery, but still below FY24 levels. The Q4 FY26 performance though is exceptional : especially that 167% profit jump which shows margins are back on track. Analyst Estimates vs Actual: Analysts expected Q4 revenue of ~₹520 Cr and PAT of ~₹58 Cr. FDC delivered ₹585 Cr revenue and ₹103 Cr PAT : comfortably beat on both counts by a wide margin. This is a genuine positive surprise. Competitors & Sector Context: Indian pharma sector had a mixed FY26. Cipla delivered strong results, while mid-size pharma peers saw pressure. FDC's 19% Q4 revenue growth stands out positively in this context. Company also received 1 USFDA approval in FY26, helping export prospects. Crux: Q4 alone is outstanding : 19% revenue growth and 167% profit jump. Full year is a recovery story after a weak FY25. Big analyst beat, improving margins, brand strength : this is a genuinely good result!

See More
PATEL ABHIKUMAR HARESHBHAI

PATEL ABHIKUMAR HARESHBHAI

12 May • 4:04 PM · SEBI-Registered Analyst

Daily Index View : SENSEX as on 12/05/2026

1. Market Trend PROBABILITY 🚨 Current Market Trend: Positive 🚀 -20% 🔍 Key Level to Watch: 77566 🔄 Current Market Surface: The trend will stay Positive until the market stay above 77566 That’s 1550 points away from the last day Closing Price of 76015 ATR 1070 2. Demand & Supply PROBABILITY Force is Demand & Supply is High if- 5. News & Macro Events has Opposite Probability then ***** & Suapply- then Mark demand & supplay probaility to 0% Last 3 days market has been flatish on downside compared to ATR, so supply has very strong firepower — it just needs sentiment support if- 5. News & Macro Events has same Probability direction as ***** & Suapply- then Mark demand & supplay probaility as given Below 11 May 2026 FII Cash-net (Buy/sell) DII Cash- net (BUY/SELL) -15% -8,438 +5,939.65 3. Reflexivity PROBABILITY FALSE FALSE Last day market rallied Intraday more than the 8-day average ATR, so it should keep its momentum intact in the first half 4. Social Proof (Global) PROBABILITY Dow Jones (Last day close) 48185 Up/Donw by 155 -5% Dow jones future (live) 49,766 Up/Donw by -26 Hang seng (Live) 26407 Up/Donw by -59 Nikki 225 (Live) 62743 Up/Donw by 325 Sentiments: Dow Jones Futures is Trading Flat to Negative & HANG SENG Index is trading Flat to Negative Today, global markets are neutral to slightly positive, and the Indian market has no strong directional bias Top stock to watchout

FDC

See More
Kundan Motwani

Kundan Motwani

30 Dec • 10:56 AM · SEBI-Registered Analyst

Stock Updates

*IndoStar Capital:* Company has approved the sale of a portion of its Commercial Vehicle Loan book to Phoenix ARC Private Limited (Neutral) *FDC Ltd:* Company has received a demand notice from the Deputy Commissioner of State Tax for FY21-22, imposing a total demand of ₹15.61 Cr (Neutral) *GNFC:* Shri Rajkumar Beniwal, IAS, has been appointed as the new Managing Director (MD) (Neutral) *Grasim:* Company/ABReN approve composite scheme moving EMIL renewables into Aditya Birla Renewables. (Neutral) *Lloyds Engineering:* Board approves Scheme of Merger by Absorption of LICL, Metalfab Hightech & Techno Industries. (Neutral)

See More
Prachi Mehta

Prachi Mehta

10 Dec • 9:33 AM · SEBI-Registered Analyst

Stocks in news today

HILINFRA
has received the Letter of Acceptance (LOA) of Rs 328.77 crore for operation at Kaza Fee Plaza on Chilakaluripet-Vijayawada section of NH-16 from Km 355.000 to Km 437.500 (Length-82.5 km) in the state of Andhra Pradesh. The Letter of Award (LOA) was issued by National Highways Authority of India (NHAI) on December 9, 2025.
VINCOFE
(VCBL) has signed a Memorandum of Understanding (MoU) with Government of Telangana on December 9,2025 at Telangana Rising Global Summit 2025, Bharat Future City, Telangana. As per the MoU, the company’s 100% subsidiary company Vintage Coffee will set up the Premium Freeze-Dried Coffee (FDC) plant in Telangana on 20 Acres land and Government of Telangana has agreed to facilitate clearances necessary for the aforesaid project under TG-IPASS. The company and Government of Telangana have come together to record their intentions through this MoU & the State Government and its agencies will extend all necessary assistance and cooperation, including expeditious grant of approvals, under the purview of the State Government, allocation of land in Food Processing Park and other approvals for speedy and successful implementation of the Project.
ADANIENT
’ wholly owned subsidiary -- Adani Airport Holdings has completed the acquisition of 99% stake in AGHPort Aviation Services (AGHPort) from Indo Thai Airport Management Services (IndoThai). Consequently, AGHPort has become a step-down subsidiary of the Company.

See More
Akshay Patel

Akshay Patel

5 Oct • 10:21 PM · SEBI-Registered Analyst

FDC
has received U.S. FDA approval for Pilocarpine Hydrochloride Ophthalmic Solution USP in 1%, 2%, and 4% concentrations, each in 15 mL packages. This approval allows the company to market these eye drops in the United States, potentially opening new revenue streams. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.

See More
Anik Mitra

Anik Mitra

19 Dec • 9:49 AM · SEBI-Registered Analyst

Stocks to Watch - I , 19 Dec 2024

BANKBARODA
FDC
BORORENEW
& many more

News & Events

Frequently Asked Questions

What is the share price of FDC Ltd.?

What is the market cap of FDC Ltd.?

Should I buy FDC Ltd. stock now?

What is the 52 week high and low of FDC Ltd.?

Is the FDC Ltd. stock good to buy?

Is FDC Ltd. a good buy for the long term?

Is FDC Ltd. overvalued or undervalued?

What is the PE and PB ratio of FDC Ltd.?

Start Now